AUS
NZ
UK
CA
USA
IND
Healius Limited is in the spotlight as activist investor Tanarra Capital aims to unlock greater value for shareholders following the recent sale of its imaging business, Lumus, for $835 million to private equity firm Affinity Equity Partners. This strategic move has led to a significant rally in Healius shares, which rose 7.5% to $1.73.
Positive Steps Forward
The sale of Lumus, which provides a range of medical imaging services including X-rays and MRIs at 150 sites, has been viewed positively by Tanarra Capital, the second-largest shareholder of Healius (ASX:HLS). According to Vidhur Rangaswamy, portfolio manager at Tanarra Capital, the price achieved for Lumus met their expectations. “We view this as a positive first step by Healius in what we expect to be a multifaceted plan to improve value for shareholders,” he noted.
Healius, previously known as Primary Health Care, is Australia’s second-largest provider of pathology services, operating around 2,000 collection centers and 95 laboratories. The company has undergone leadership changes and faced profitability pressures, with its share price dropping to $1.10 in early May.
Strategic Review and Simplification
Following increased pressure from investors, Healius conducted a strategic review led by UBS, which ultimately led to the decision to sell Lumus. Chief Executive Paul Anderson stated that this divestment would streamline Healius’s operations, reducing capital expenditure requirements. “Now, this is all about execution,” Anderson emphasized, highlighting a focus on enhancing efficiency and advancing digitization within the pathology segment.
The Lumus deal was structured at an enterprise value of $965 million, including debt, with Healius expected to receive cash proceeds of $835 million once all lease liabilities are accounted for. Some of this capital will be returned to shareholders, further signaling the company's commitment to enhancing shareholder value.
Future Growth Potential
Mark Chudek, managing director at Affinity Equity Partners, remarked that the acquisition aligns with their strategy of investing in high-quality companies with significant growth potential. Tanarra Capital has expressed optimism regarding the future value of the Lumus business under new ownership, suggesting that private equity firms typically seek to sell assets within three to five years at significantly higher valuations.
Tanarra Capital’s involvement with Healius forms part of its long-term value fund, which also includes stakes in several prominent ASX-listed companies like Lendlease. Their advocacy has previously led to strategic changes that aim to restore returns.
Healius Limited is taking strategic steps to enhance shareholder value following the successful divestment of its Lumus business. With a focus on improving operational efficiency and advancing digital capabilities in pathology, the outlook appears promising for both the company and its investors.
